Fatty Acid Binding Protein 4 (FABP4, aP2) is a cytoplasmic fatty acid chaperone, expressed primarily in adipocytes and myeloid cells and implicated in the development of insulin resistance and atherosclerosis. Here we demonstrate that FABP4 triggers the ubiquitination and subsequent proteasomal degradation of PPARγ, a master regulator of adipogenesis and insulin responsiveness. Importantly, FABP4-null mouse pre-adipocytes as well as macrophages exhibited increased expression of PPARγ, and complementation of FABP4 in the macrophages reversed the increase in FABP4 expression. The FABP4-null pre-adipocytes exhibited a remarkably enhanced adipogenesis compared to WT cells, indicating that FABP4 regulates adipogenesis by down-regulating PPARγ. We found that FABP4 level was higher and PPARγ level was lower in human visceral fat and mouse epididymal fat compared with their subcutaneous fat. Furthermore, FABP4 was higher in adipose tissues of obese diabetic individuals compared to healthy ones. Suppression of PPARγ by FABP4 in visceral fat may explain the reported role of FABP4 in the development of obesity-related morbidities, including insulin resistance, diabetes, and atherosclerosis.
Adiposity is closely correlated with important physiological parameters such as blood pressure, systemic insulin sensitivity, dyslipidemia and serum triglyceride levels (1; 2), rendering obesity to an independent risk factor for myocardial infarction, stroke, type 2 diabetes mellitus, and certain cancers (3) . Among adipose tissues, visceral fat is more closely correlated with obesity-associated pathology than overall adiposity (4-8).
The nuclear receptor PPARγ is a master regulator of adipose cell differentiation, playing a critical role in systemic lipid and glucose metabolism (9) . PPARγ is activated by natural or synthetic agonists such as the anti-diabetic thiazolidinedione (TZD) (10) .
Activated PPARγ is a master regulator of adipogenesis, acting as a transcription factor of genes expressed in mature adipocytes, including FABP4, CD36, lipoprotein lipase (LPL) and adiponectin, all of which containing peroxisome proliferator response elements (PPREs) (11) . PPARγ is also expressed in myeloid cells, and its activation promotes an anti-inflammatory phenotype (11) . Disruption of PPARγ specifically in myeloid cells also predisposes mice to the development of diet-induced obesity, insulin resistance, and glucose intolerance (12) , whereas activation of PPARγ within macrophages promotes lipid efflux, thereby stabilizing atherosclerotic lesions (13) .
A major target gene of PPARγ is the lipid transporter FABP4, also known as aP2 (14) .
PPARγ induces FABP4 almost exclusively in adipocytes and macrophages. FABP4 acts as a fatty acids chaperone, which couples intracellular lipids to biological targets and signaling pathways (15; 16) . FABP4 has been implicated in several aspects of the metabolic syndrome in mice, including insulin resistance and atherosclerosis (17) (18) (19) (20) (21) (22) . In humans, a T87C polymorphism in the FABP4 promoter leads to reduced transcriptional activity, resulting in lower serum triglycerides and a reduced risk of atherosclerosis and type 2 diabetes (23). In addition, the level of circulating human FABP4 was proposed as an independent prognostic marker for future development of diabetes (24; 25) . Furthermore, PPARγ is considered a tumor suppressor gene (11) , whereas FABP4 has a role in tumorigenesis (26; 27) .
Understanding the mechanisms by which obesity alters adipose tissue biology is of major importance because the fat tissue acts as an endocrine organ that regulates systemic metabolism (28) . Visceral adipose tissues (VAT) and subcutaneous adipose tissues (SAT) are functionally distinct and many clinical studies led to the conclusion that VAT rather than SAT is the key factor inducing the metabolic syndrome, also serving as a source of inflammatory and stress-promoting factors (8; 29-31) .
To date, the mechanisms by which FABP4 promotes insulin resistance and inflammation are not fully understood. The fact that FABP4 is induced by PPARγ but exerts metabolic and immunologic activities opposite to those of PPARγ led us to hypothesize that FABP4 might be involved in regulating PPARγ activity. Here we show that FABP4 negatively regulates PPARγ levels in macrophages and in adipocytes, thereby attenuating adipocyte differentiation; we elucidate a mechanism involving proteasomal PPARγ degradation and further demonstrate elevated FABP4/PPARγ ratio in intra-abdominal fat compared with SAT in mice and VAT compared with SAT in humans.
RESEARCH DESIGN AND METHODS

Cells and Reagents.
Human THP-1 (TIB-202) cells, human HEK 293T cells, HeLa (CCL-2.1) cells, mouse NIH-3T3 fibroblasts (CRL-1658) and mouse 3T3-L1 preadipocytes (CL-173) were from the ATCC. Immortalized WT and FABP4-null preadipocytes, as well as immortalized WT, FABP4-null and FABP4-complemented macrophage cell lines were generated from WT and FABP4-null mice as previously described (22; 32) . 3T3-L1 cells and pre-adipocytes from FABP4 KO and WT mice were grown in DMEM containing 10% Bovine Serum (BS). THP-1 cells and immortalized macrophage cell lines were grown in RPMI 1640 medium containing 10% FBS, 2 mM Lglutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES and 1 mM sodium pyruvate. All other cell lines were grown in DMEM with 10% FBS (GibcoBRL), 100 IU/ml penicillin and 0.1 mg/ml streptomycin. The FABP4 inhibitor BMS309403 and the proteasome inhibitor MG262 were from Calbiochem. Rosiglitazone was from Cayman Chemical. JetPEI™ transfection reagent was from Polyplus-transfection. siRNA oligonucleotides were from Dharmacon. Cell Line Nucleofector kit V was used for siRNA transfections of THP-1 cells (Amaxa GmbH, Cologne, Germany). All other reagents were from Sigma.
Differentiation of THP-1 Cells and Pre-Adipocytes. THP-1 cells (1x10 6 /ml) were induced to differentiate by PMA (100 nM, 24 h). For experiments in which BMS309403 was included, the medium was supplemented with 10% lipoprotein deficient serum (LPDS) instead of 10%FBS. 3T3-L1 pre-adipocytes were differentiated as described (33) .
Briefly, cells were sub-cultured at <70% confluence. To induce differentiation, confluent cell cultures were placed in medium containing 0.5 mM 1-Methyl-3-Isobutylxanthine (IBMX), 1 µM dexamethasone, and 5 µg/ml insulin in 10% FBS/DMEM for 48 h. Next, the medium was changed, and 5 µg/ml insulin was added for another 48 h. The medium was then replaced with 10% FBS/DMEM, and was renewed every 2 days until the cells became fully differentiated and lipid droplets were apparent. were then analyzed for luciferase activity and normalized to Renilla activity using the (Fig. 1E ). These findings suggested that FABP4 negatively regulates PPARγ-mediated genes activation during adipogenesis.
We then studied the interrelationships of FABP4 and PPARγ in vivo, comparing wild type mice with FABP4-null mice (17) . We found that white adipose tissue of FABP4-null mice had a 2.7 fold higher level of PPARγ compared with that of WT mice (Figs. 2A, B) .
Furthermore, immunoblotting of extracts from immortalized WT and FABP4-null mouse macrophages, as well as immortalized FABP4-null macrophages, in which FABP4 expression was complemented, demonstrated that FABP4 deficiency led to higher expression of PPARγ, and that complementation of FABP4 expression reduced the expression level of PPARγ (Fig. 2C ). In contrast with the protein level, FABP4 had no significant effect on the level of PPARγ mRNA in these cells (Fig. 2D) . These results suggested that FABP4 regulates PPARγ at the protein level.
FABP4 attenuates adipogenesis.
We then studied the role of FABP4 in adipogenesis.
Upon induction of differentiation, we found that the FABP4-null adipocytes accumulated a larger number and a larger volume of lipid droplets compared with those accumulated in WT adipocytes (Figs. 3A, B) . The enhanced adipogenesis in the FABP4-null adipocytes was apparent when the differentiation was performed both in the absence and 3C, D) . PPARγ activity was also higher in the FABP4-null adipocytes, as evaluated by the level of adiponectin, both in the absence and presence of rosiglitazone (Fig. 3C, lower panel). We therefore propose that FABP4 attenuates the formation of fat cells by downregulating the master regulator of adipogenesis, PPARγ. We noticed that the FABP4 null adipocytes exhibited stronger Oil red O staining compared with rosiglitazone-treated WT adipocytes (Fig. 3B) , suggesting that FABP4 inhibition might be more effective in promoting insulin sensitivity than this antidiabetic drug. (Fig. 4C) . This result indicates that FABP4 interferes with PPARγ activation both by its endogenous ligands and by its pharmacological ligands.
FABP4 accelerates the proteasomal degradation of PPARγ. Because PPARγ mRNA levels were not affected by FABP4 silencing (Fig. 1A) , we studied the possible regulation of PPARγ by FABP4 at the protein level. To this end, we followed the rate of PPARγ decay in the presence of cycloheximide, an inhibitor of protein synthesis. Human 293T cells were transfected with pPPARγ, and either control vector (pCS6) or pFABP4.
Cycloheximide was then added; whole cell extracts were prepared at various times and immunoblotted with a PPARγ antibody. Co-expression of FABP4 with PPARγ reduced the half-life of PPARγ at all time points (Figs. 5A, B) . Thus, it is likely that FABP4 accelerates the rate of PPARγ degradation.
We then examined PPARγ levels in the presence of the proteasome inhibitor MG262.
Human HeLa and mouse NIH-3T3 cells were transfected with pPPARγ and either pFABP4 or the control vector pCS6. MG262 abolished the FABP4-mediated reduction of PPARγ levels in both human and mouse cells (Figs. 5C, D) . MG262 increased the level of PPARγ even in the absence of FABP4 (Fig. 5D) , supporting an earlier report that the basal turnover of PPARγ is mediated by proteasomal degradation (36) . These experiments suggest that FABP4 accelerates the proteasomal degradation of PPARγ. (Fig. 6A) . Upon co-expression of PPARγ and FABP4 the level of free PPARγ was reduced and expression of the ubiquitin-conjugated PPARγ practically disappeared (Fig. 6A) . Over-expression of FABP4 robustly increased the conjugation of HA-ubiquitin to PPARγ, as determined by inhibiting its proteasomal degradation with MG262 (Fig. 6A, compare lanes 5 & 6) .
We were also able to detect endogenous untagged ubiquitin conjugates of PPARγ using anti-ubiquitin antibody. Human 293T cells were co-transfected with pPPARγ and either pFABP4 or a control vector. In the absence of FABP4, mono-ubiquitinated PPARγ was the main conjugate as determined by immunoprecipitation with anti PPARγ antibody followed by immunoblotting with anti-ubiquitin antibody (Fig. 6B, lane 2) . Upon coexpression of FABP4 and PPARγ, the level of the mono-ubiquitinated PPARγ was Page 10 of 28 Diabetes reduced, whereas the level of the poly-ubiquitinated forms of PPARγ increased (Fig. 6B,   compare lanes 2 & 3) . As expected, MG262 considerably elevated the polyubiquitination of PPARγ and further reduced the level of the mono-ubiquitinated PPARγ (Fig. 6B, compare lanes 4 & 5 to 2 &3) . These experiments suggest that FABP4 triggers the proteasomal degradation of PPARγ by increasing its poly-ubiquitination. Unlike the case of PPARγ, co-expression of FABP4 with p53, a protein extensively characterized as a target of ubiquitin-dependent proteasomal degradation (37), had no effect on the protein level of p53, thereby demonstrating the specific effect of FABP4 on PPARγ degradation (Fig. 6C) .
FABP4 is increased and PPARγ is reduced in mouse epididymal fat compared with subcutaneous fat. Because both FABP4 and visceral fat are implicated in obesity-related morbidities, we compared the expression of FABP4 and PPARγ in adipose tissues of mouse subcutaneous fat and epididymal fat, which resembles visceral fat in humans. In both WT and FABP4-null mouse strains, expression of FABP4 was higher in epididymal fat compared to subcutaneous fat, in correlation with reduced amounts of PPARγ (Figs.   7A, B) . Similarly, PPARγ expression in adipose tissues of WT mice was reduced compared to its level in FABP4-null fat (Figs. 7A, B) . These findings further confirm the role of FABP4 as a negative regulator of its master regulator PPARγ and demonstrate how these two genes are differentially expressed in the functionally distinct fat depots.
Although the level of PPARγ in FABP4-null epididymal fat appears to be somewhat lower compared with that in subcutaneous fat, analysis of paired samples did not show a statistically significant difference between the levels of PPARγ in the mouse epididymal and subcutaneous fat (n=4 pairs, P=0.602).
FABP4 is up-regulated in human visceral fat compared to subcutaneous fat. We then measured the relative amount of FABP4 and PPARγ in paired samples of human VAT and SAT obtained from biopsies of lean (6), obese (11) and obese diabetic (9) individuals (Figs. 7C, D) . VAT FABP4 of each individual was normalized to its SAT FABP4 level.
No significant difference in the VAT/SAT ratio of FABP4 was observed upon comparing lean and healthy obese individuals. However, the VAT/SAT ratio of FABP4 was significantly higher in obese diabetic patients compared with lean or healthy obese individuals (Fig. 7D) . Consistent with our previous results, PPARγ was negatively correlated with FABP4, and was higher in the human SAT, compared with the human VAT (Fig. 7E) .
DISCUSSION
The fatty acid chaperone FABP4 is induced by PPARγ, the master regulator of adipogenesis, yet these two regulators exert opposite effects on various metabolic parameters such as insulin resistance and inflammation (14) . Here we demonstrate a previously unrecognized negative feedback loop, whereby FABP4 specifically triggers proteasomal degradation of PPARγ and consequently inhibits PPARγ-related functions, thereby providing a possible mechanism that explains their opposite effects. Our observations are consistent with an earlier finding that PPARγ activity is elevated in FABP4-null macrophages (20) . FABP4 was reported to physically interact with PPARγ (38) , hence, it is likely that such a physical interaction triggers the ubiquitination and the subsequent proteasomal degradation of PPARγ. This interaction took place through a site distinct from the fatty acid binding pocket of FABP4 (38) Pharmacologic activators of PPARγ such as TZDs significantly improve insulin sensitivity in type 2 diabetes and the net effect of PPARγ activation in murine macrophages is atheroprotective (13) . However, TZDs trigger rapid degradation of PPARγ (36) , possibly accounting for the recent reports implicating them in increased risk of cardiovascular death (50). We propose that similarly to TZD, FABP4 lowers PPARγ levels in macrophages, thereby triggering its adverse physiological effects (11) . In this respect, inhibition of FABP4, combined with activation of PPARγ by TZDs could attenuate the harmful effects of TZDs, while maintaining its beneficial activities. 
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